AstraZeneca Reports the Results for the Combination of Imfinzi, TACE, and Bevacizumab in P-III Trial for Hepatocellular Carcinoma (HCC)
Shots:
- The P-III (EMERALD-1) trial evaluates Imfinzi + TACE + bevacizumab vs TACE alone in patients (n=616) with unresectable HCC across 18 countries. The 1EP of the study includes PFS for Imfinzi + TACE + bevacizumab & 2EPs include PFS for Imfinzi + TACE, TTP, OS & ORR
- As per the results (presented at ASCO GI 2024), Imfinzi + TACE + bevacizumab reduced the risk of disease progression by 23% vs TACE alone with a mPFS of 15mos. with combination therapy vs 8.2mos, a TTP of 22mos. vs 10mos. & ORR of 43.6% vs 29.6%
- The company expects to continue the P-III (EMERALD-1) study to evaluate the 2EP of OS. Imfinzi is a human mAb that binds to the PD-L1 protein & blocks the interaction of PD-L1 with the PD-1 & CD80 proteins
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Received NMPA Approval for Imfinzi + CT to Treat Patients with Locally Advanced/metastatic Biliary Tract Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
